Ridgeline Discovery
Ridgeline Discovery is a Basel-based biotech company-creation platform operating as the European Discovery Engine for Versant Ventures, sourcing academic and industry science to found and operate new therapeutic biotech companies across Europe, the US, and RoW.
- Company typePrivate
- Founded2017
- HeadquartersBasel, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Ridgeline Discovery does
Ridgeline Discovery GmbH is a Basel-based biotech company-creation platform that operates as the European Discovery Engine for Versant Ventures, a healthcare venture capital firm with $5.5 billion under management. Founded in 2017, Ridgeline sources academic and industry science across Europe, the US and Rest of World, then partners with entrepreneurs to build new biotech companies around therapeutic platforms — taking them from inception through Series B, pharma partnerships, IPO, or trade sale. The firm runs a Source → Discover → Build operating model delivered by a small operating team (11–50 employees) that also serves as Versant Operating Partners.
Its core product is the Ridgeline Discovery Platform itself: a repeatable company-building service combining senior R&D leadership with Versant capital. Active portfolio companies include Cimeio Therapeutics (applied gene editing, cellular and immunotherapy with Shielded-Cell & Immunotherapy Pairs for genetic diseases, hematologic malignancies, and autoimmune disorders), SixPeaks Bio (antibody-based compounds for obesity and co-morbidities), and Granite Bio (modulation of central disease biology nodes for inflammatory, autoimmune, and fibrotic conditions). Alumni portfolio companies that now operate fully independently include Black Diamond Therapeutics (precision cancer medicines, Nasdaq IPO January 2020), Bright Peak Therapeutics (engineered cytokines for immuno-oncology), Monte Rosa Therapeutics (protein degradation pathway cancer therapeutics), and Firefly Bio (degrader antibody conjugates for cancer).
The business model is built on venture economics rather than product pricing: Ridgeline is funded by Versant as a cost-efficient operating arm, while value capture flows through equity in the portfolio companies and downstream exit returns to the fund. Revenue is not publicly disclosed, and the company is organized as a Swiss GmbH (Ridgeline Discovery GmbH) with two Basel locations — a headquarters office at Aeschenvorstadt 36 (c/o Versant Ventures) and an offices-and-labs facility at the Basel Technologiepark on Hochbergerstrasse. The leadership bench — Andrew Jefferson (COO, ex-Roche BD), Giorgio Ottaviani (Head of R&D, ex-Roche and Novartis), Alexander Mayweg (Versant Managing Director, ex-Roche Global Head of Chemistry), Brad Bolzon (Versant Chairman, ex-Roche and Eli Lilly), Markus Enzelberger (ex-MorphoSys CSO), Nigel Sheail (ex-Novartis Head of M&A and BD) — reflects the firm's positioning as a pharma-experienced operating layer for academic and early-stage science.
Ridgeline Discovery firmographics
Firmographics- Name
- Ridgeline Discovery
- Legal name
- Ridgeline Discovery GmbH
- Website
- https://ridgelinediscovery.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Ridgeline Discovery is a Basel-based biotech company-creation platform operating as the European Discovery Engine for Versant Ventures, sourcing academic and industry science to found and operate new therapeutic biotech companies across Europe, the US, and RoW.
- Ownership category
- akta.pro rank
Ridgeline Discovery industry classification
Industry- Product category
- Biotech Venture Creation
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)
Keywords
Where Ridgeline Discovery is headquartered
LocationHeadquarters
- HQ city
- Basel
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
Ridgeline Discovery business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Marketing channels2 records
Ridgeline Discovery product offering
Product offeringCore offering
Ridgeline Discovery is a Versant Ventures Discovery Engine that creates and operates new biotech companies in partnership with entrepreneurs, industry, and leading academics across Europe, the US, and Rest of World. The firm sources breakthrough academic science, deploys an international team of experienced drug discovery professionals to drive research into novel therapeutic platforms and candidates, and builds, operates, and grows those companies toward independent status via Series B financings, IPOs, pharma partnerships, and trade-sale exits.
Product overview
Ridgeline Discovery is a Versant Ventures Discovery Engine that operates as a biotech company creation platform. The core offering is a comprehensive company-building service that partners with entrepreneurs and academics to access breakthrough science, drive research to create novel platforms and therapeutic candidates, and build companies with deep operational expertise. The portfolio includes current companies: Cimeio Therapeutics (gene editing/cellular immunotherapy), SixPeaks Bio (antibody-based obesity treatments), and Granite Bio (inflammatory/autoimmune/fibrotic conditions). Alumni companies that have become independent include Black Diamond Therapeutics (precision cancer medicines, IPO 2020), Bright Peak Therapeutics (engineered cytokines for immuno-oncology), Monte Rosa Therapeutics (protein degradation pathways for cancer), and Firefly Bio (degrader antibody conjugates for cancer).
Differentiator
Problem solved
Functional benefit
Products and services
- Ridgeline Discovery Engine Biotech company creation and operating platform that partners with entrepreneurs, industry, and leading academics across Europe, the US, and Rest of World to access breakthrough science, drive research into novel therapeutic platforms and candidates, and build, operate, and grow independent biotech companies.
Companies that use Ridgeline Discovery
Customer profileSegments1 record
Ideal customer profiles2 records
Ridgeline Discovery technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Ridgeline Discovery partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered flagship, core and minor.
- Black Diamond TherapeuticsflagshipPortfolio company that operates fully independently. Black Diamond Therapeutics is a Ridgeline-built company focused on precision cancer medicines for patients with genetically defined cancers driven by oncogenes activated by allosteric mutations. IPO January 2020.
- Bright Peak TherapeuticsflagshipPortfolio company that operates fully independently. Bright Peak is developing next-generation engineered cytokines for immuno-oncology indications.
- Monte Rosa TherapeuticsflagshipPortfolio company that operates fully independently. Monte Rosa is developing cancer therapeutics that modulate protein degradation pathways.
- Cimeio TherapeuticscoreRecently founded company operating in collaboration with Ridgeline. Cimeio is an applied gene editing, cellular, and immunotherapy company developing Shielded-Cell & Immunotherapy Pairs for patients with genetic diseases, hematologic malignancies, and severe autoimmune disorders.
- Granite BiocoreRecently founded company operating in collaboration with Ridgeline. Granite Bio's differentiated approach impacts central disease biology nodes to transform inflammatory, autoimmune and fibrotic conditions.
- SixPeaks BiocoreRecently founded company operating in collaboration with Ridgeline. SixPeaks focuses on advancing a portfolio of antibody-based compounds targeting obesity and associated co-morbidities.
- Firefly BiominorAlumni company that was part of Ridgeline portfolio. Firefly has developed a novel platform to treat cancer using degrader antibody conjugates (DACs). Located in South San Francisco, California.
Scale indicators2 records
Recent moves7 records
Expansion highlights4 records
Ridgeline Discovery competitors and assessment
Company assessmentDirect peers
- Flagship Pioneering: Biotech venture creation firm that originates and builds multiple platform companies around breakthrough science — directly comparable to Ridgeline's Discovery Engine model of company-building in drug discovery.
- Arch Venture Partners: Long-running biotech-focused venture firm that creates and funds multiple therapeutics platforms, often in collaboration with academic founders — directly comparable discovery-and-build investment model.
- Atlas Venture: Biotech-focused VC that builds new company platforms around academic science and operates them through Series A, similar in operating orientation to Ridgeline.
- Inception Sciences (Versant Discovery Engine): Sibling Versant Discovery Engine that creates and operates Versant-backed biotech companies; effectively the closest structural parallel to Ridgeline within the same sponsor's portfolio of company-creation platforms.
- Medicxi: European biotech-focused venture firm that backs single-asset 'asset-centric' companies derived from pharma partnerships — comparable model of building focused biotechs around specific drug discovery programs.
Broad incumbents
- Versant Ventures: Ridgeline's parent and primary capital provider; a $5.5B healthcare VC running multiple Discovery Engines including Ridgeline — closely analogous in operating model, with broader scope across North America and Europe.
- Roivant Sciences: Public biomedical venture builder that acquires/invents assets and spins them into Vants; broader scope but overlapping 'company-creation' ethos with Ridgeline.
- BridgeBio Pharma: Biotech that creates and operates multiple asset-focused subsidiaries around genetically defined diseases — overlaps with Ridgeline's build-and-operate model.
- Bayer Leaps by Bayer: Strategic venture arm of Bayer that invests in breakthrough biotech platforms and helps build companies; overlaps with Ridgeline's discovery-to-build workflow.
Emerging players
- Lighthouse Pharma: European biotech studio/venture builder model focused on building companies around academic science — comparable emerging European discovery-to-company model to Ridgeline.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Ridgeline Discovery social profiles
Digital presenceRidgeline Discovery financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ridgeline Discovery leadership team
Management profileNumber of profiles
Profiles8 records
Ridgeline Discovery subsidiaries and ownership
Company hierarchySubsidiaries3 records
Ridgeline Discovery funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ridgeline Discovery M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ridgeline Discovery
What does Ridgeline Discovery do?
Ridgeline Discovery is a Versant Ventures Discovery Engine that creates and operates new biotech companies in partnership with entrepreneurs, industry, and leading academics across Europe, the US, and Rest of World. The firm sources breakthrough academic science, deploys an international team of experienced drug discovery professionals to drive research into novel therapeutic platforms and candidates, and builds, operates, and grows those companies toward independent status via Series B financings, IPOs, pharma partnerships, and trade-sale exits.
Is Ridgeline Discovery a public or private company?
Ridgeline Discovery is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ridgeline Discovery founded?
Ridgeline Discovery was founded in 2017. It employs 11 to 50 people.
Where is Ridgeline Discovery based?
Ridgeline Discovery is headquartered in Basel, Switzerland, in the Europe region.
Who are Ridgeline Discovery's main competitors?
Direct peers on record are Flagship Pioneering, Arch Venture Partners, Atlas Venture, Inception Sciences (Versant Discovery Engine) and Medicxi. Broad incumbents are Versant Ventures, Roivant Sciences, BridgeBio Pharma and Bayer Leaps by Bayer. Lighthouse Pharma is listed as an emerging player.
Does Ridgeline Discovery have an API?
No public API is recorded for Ridgeline Discovery.
What industry is Ridgeline Discovery in?
Ridgeline Discovery's product category is Biotech Venture Creation. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 8731.